Ensign Peak Advisors
SABS icon

Ensign Peak Advisors’s SAB Biotherapeutics SABS Stock Holding History

Ensign Peak Advisors’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.27M Buy
+1,375,610
New +$5.49M 0.01% 522

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ensign Peak Advisors's SABS Position: Q1 2026 in Review

Ensign Peak Advisors opened a new position in SAB Biotherapeutics (SABS) in Q1 2026: 1,375,610 shares worth $5.27M. The stake represents 0.01% of the portfolio and ranks #522 among its holdings.

76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Ensign Peak Advisors held 1,375,610 shares of SAB Biotherapeutics worth $5.27M as of Q1 2026.
  • SAB Biotherapeutics was a new Ensign Peak Advisors position in Q1 2026.
  • SAB Biotherapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #522 holding.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.